Archive for Articles

Supernus Pharmaceuticals, Inc (SUPN) – upcoming IPO profile

Apr 29, 2012 No Comments

Initial Public Offering listing on Nasdaq Global Select Market under the symbol “SUPN” likely week of Apr 30-May 4, 2012. Pipeline: SEVERAL upcoming catalysts SPN-538 (extended release topiramate) for epilepsy. NDA filed with PDUFA date in July 2012. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. Topiramate […]

Read more

BioPharmCatalyst ASCO 2012 Calendar has been added!

Apr 26, 2012 No Comments

I am pleased to announce that the ASCO 2012 Calendar has been added to BioPharmCatalyst. You can find it next to the FDA Calendar tab. Abstract numbers, presentation types and times, drugs and indications are all available in the calendar.  Links to abstracts will be added as soon as they are uploaded onto the ASCO website on […]

Read more

Financial Database Update – 4Q 2011 Cash Positions uploaded

Apr 09, 2012 No Comments

The Financial Database has been updated to include cash positions as of the end of 2011 for approximately 175 small and mid cap biotech companies. This is the second quarter where cash positions have been inputted, allowing readers to compare cash positions of various companies from the previous quarter. In order to get a much more […]

Read more

Weekly Summary of key pharma events – week ended January 13 2012

Jan 14, 2012 No Comments

See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS Delcath Systems, Inc. (Nasdaq: DCTH) intends to refile its NDA during 2Q 2012 for the treatment of patients with metastatic melanoma in the liver. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) – PDUFA date of June 27 set for lorcaserin in patients with obesity. AVEO Pharmaceuticals, Inc. (NASDAQ: […]

Read more

BMY wasn’t alone in bidding for INHX

Jan 14, 2012 No Comments

As many of you may be aware BMY offered INHX $26 per share for its acquisition last week.  I posted on twitter a link detailing a SEC filing noting that it had offered $20/share just the previous week only to be informed that it needed to increase its bid as another company was offering more. I have pasted […]

Read more

New tool added to Financial Database – View S-3 shelf filings for all companies

Jan 10, 2012 No Comments

Readers now have the opportunity to view recent S-3 shelf filings in the Financial Database. Such a filing is required to comply with SEC regulations before filing a public offering. S-3 filings remain valid for up to three years. A shelf offering is not an immediate offering of shares. Rather, it gives the company an option to sell […]

Read more

Weekly Summary of key pharma events – week ended January 6 2012

Jan 07, 2012 No Comments

See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) said that it intends to file its NDA for tivozanib during 2012 following full data release at ASCO this year. Cornerstone Therapeutics (NASDAQ: CRTX) – NDA for lixivaptan for the treatment of hyponatremia was filed on Dec. 29, […]

Read more

Merry Xmas – Summary of pharma events week ending 12/23/12

Dec 23, 2011 No Comments

A Merry Xmas to all readers of BioPharmCatalyst. Thank you all for your support over the past year and wish you all a relaxing break with friends and family! See individual posts made in the last week for more detail.   PDUFA/FDA RELATED EVENTS Santarus, Inc. (NASDAQ: SNTS) submitted its NDA for UCERIS for mild to […]

Read more

Companies facing NASDAQ delist or reverse splits in 2012

Dec 23, 2011 No Comments

If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 10 […]

Read more

A look back at reverse split and NASDAQ-delist projections made in August 2011

Dec 22, 2011 No Comments

On August 1, 2011, I listed seven companies facing NASDAQ delist or a reverse split to remain listed on NASDAQ. I now follow up the list by firstly noting my prediction, then what actually happened. You can read the original post HERE and results of other projections HERE. (First bracket indicates price as of August […]

Read more

Weekly Summary of key pharma events – week ended 12/16/11

Dec 17, 2011 No Comments

See individual posts made in the last week for more detail. PDUFA/FDA RELATED EVENTS NeurogesX, Inc. (Nasdaq:NGSX) will meet with the FDA Anesthetic and Analgesic Drug Products Advisory Committee on February 9, 2012 to discuss the available efficacy and safety data for sNDA of QUTENZA for the management of neuropathic pain related to HIV-associated peripheral neuropathy. Isis Pharmaceuticals, […]

Read more